The M2GEN AVATAR program collects and studies consented cancer patients’ biospecimens and companion clinical information for the development of improved oncology treatments. Through construction of comprehensive genotypic, transcriptomic and phenotypic cohorts of consented cancer patients, M2GEN generates in silico AVATARs. M2GEN uses this information to accelerate cancer research, clinical trial matching, and development of real world data comparator cohorts. The breadth and scope of the AVATAR clinical and molecular data enables the utilization and discovery of a wide array of DNA and RNA biomarkers, including those biomarkers associated with response to immuno-oncology agents.
Contributing to the ORIEN Avatar program, Discovery Life Sciences’ sequencing and bioinformatics laboratory, HudsonAlpha Discovery, has conducted high yield, high quality dual RNA/DNA isolation from FFPE specimens, whole exome sequencing and RNA sequencing services on more than 30,000 tumor and non-tumor samples. These genetic results, sharpened by ORIEN’s clinical data and the significant size of the sample set, accurately expound known drivers of cancer, identify new genetic alterations and reveal novel potential therapeutic targets.